Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
A key question for investigators conducting clinical trials has changed direction. Instead of asking why they should share data with other researchers or drug and medical device manufacturers, they’re more likely to ask how to disseminate the information.
Reluctance to share data has been the norm rather than the exception, leading to fewer published clinical trial results and a dearth of independent reanalyses that could confirm original results. For example, a study of clinical trials that were completed in 2009 found only 22% complied with a mandate to report summary results on ClinicalTrials.gov within 1 year of completion (Prayle AP et al. BMJ. 2012;344:d7373). And another study looking at 37 reanalyses of data from randomized clinical trials found only 5 were performed entirely by independent authors (Ebrahim S et al. JAMA. 2014;312:1024-1032).
Mitka M. Clinical Trial Data: Share and Share Alike?. JAMA. 2015;313(9):881–882. doi:10.1001/jama.2015.481
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: